Human retinal organoids: A breakthrough in dry age-related macular degeneration therapy
New study identifies metformin and TN1 as potential therapeutic targets for dry AMD
image: (A) Bright-field images of human ROs at D7 after the application of different concentrations of sodium iodate (0, 0.1, 1 and 10 mM). (B) Representative confocal images of TUNEL apoptosis staining of sections from the control and NaIO3 injury groups of ROs on day 7 showing apoptotic cells after the application of sodium iodate. (C) The percentage of apoptotic cells increased with increasing sodium iodate concentration. (n=6/group). (Data are shown as the mean ± SD. Statistical analyses are determined by One-way ANOVA, followed by Tukey’s test. ***P < 0.001).
Credit: Xiaolu Hao, Lu Du, Guang Liu, Zhaohui Li, Shaojun Wang
Age-related macular degeneration (AMD), classified into dry and wet types, poses a significant threat to the vision of the elderly population globally. Despite its prevalence, the exact molecular mechanisms underlying the damage to retinal pigment epithelial cells (RPEs) and photoreceptor cells (PCs) in dry AMD remain poorly understood. Hence, there is a critical need for the development of human retinal models that can mimic dry AMD.
This research, published in the Genes & Diseases journal by a team from The Third Medical Center of Chinese PLA General Hospital, Medical School of the Chinese PLA General Hospital, and Chinese Academy of Medical Sciences & Peking Union Medical College, utilized human retinal organoids (ROs) stimulated with sodium iodate to establish a dry AMD model.
Building on their earlier work, which demonstrated the presence of abundant RPEs and PCs in ROs after 186 days of differentiation, the researchers developed a human retinal degeneration model (hRO-AMD) by adding sodium iodate to the culture environment, which simulated the key pathological processes of human dry AMD.
Subsequently, the team identified two compounds—metformin, a widely used anti-diabetic drug, and TN1, a fetal hemoglobin (HbF) inducer—as having protective effects against retinal degeneration. Interestingly, both metformin and TN1 significantly reduced sodium iodate-induced apoptosis in ROs, decreased oxidative stress in photoreceptors and alleviated RPE cell damage, thus providing a protective effect on the retina.
Further RNA-seq analysis revealed that both metformin and TN1 exerted their protective effects through upregulation of the HMOX1 gene, which is involved in resistance to oxidative stress. Taken together, these findings suggest that HMOX1 may be an important molecule mediating the protective effects of metformin and TN1 against oxidative stress-induced injury.
The researchers acknowledge that the current model does not yet fully simulate all aspects of dry AMD pathogenesis, such as vascular and immune cell involvement. Nonetheless, the hRO-AMD model could serve as a powerful tool to uncover novel therapeutic targets. In conclusion, this oxidative stress injury model of ROs can provide valuable insights for the development of new therapies for dry AMD via targeting HMOX1 and its downstream pathways.
Reference
Title of Original Paper: Human Retinal Organoids for Modelling Dry Age-Related Macular Degeneration and Screening Drugs
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI: https://doi.org/10.1016/j.gendis.2025.101593
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus Cite Score: 8.4 | Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases)